Proteomic Analysis of Rat Brains Following Exposure to Electroconvulsive Therapy by Lee, Cheol Soon et al.
INTRODUCTION
Electroconvulsive therapy (ECT) results in electrically in-
duced repetitive firing of neurons in the central nervous sys-
tem; it is a technique that has been used to treat severe psy-
chiatric illness. Major depression, especially in the elderly, is
currently the most common indication for ECT. However, it
is also used in other serious psychiatric disorders such as sc-
hizophrenia and bipolar I disorder. It has been shown to be
effective in between 85% and 90% of cases of major depres-
sion; by comparison, antidepressant medications have been
shown to be effective in 60-65% of cases (1). Understanding
the mechanism by which ECT improves the symptom of
major depression might provide a clue to better understand-
ing involved in the etiology of depression. Despite the early
recognition of the essential role of generalized seizure activi-
ty in producing the therapeutic effects, the exact mechanisms
of action of ECT have remained to be elucidated.
The human genome project has provided a wealth of infor-
mation on the sequences of individual genes. However, the
decoding of the nucleic acid sequence alone is not sufficient
to understand the complex biological processes and the mech-
anisms underlying diseases; the analysis of mRNA and pro-
tein function is necessary to advance understanding (2, 3).
Therefore, the focus of research is now moving to the immense
task of identifying the structure, function and the interactions
of the proteins produced by individual genes. Proteins are key
molecules to understand cellular functions, disease processes,
and chemotherapeutic treatments; this area of research of the
analysis of cellular proteins has been termed proteomics (4).
Recent improvements for proteome analysis have offered the
possibility of identifying disease-associated protein markers
to assist in diagnosis or prognosis, and for selecting potential
targets for specific drug therapy.
In this study, we prepared proteins from ECT-treated and
normal rat brain tissues, and then analyzed and identified a
number of ECT-associated proteins by two-dimensional gel
electrophoresis and matrix-assisted laser desorption/ioniza-
tion time-of flight (MALDI-TOF)/mass spectrometry.
MATERIALS AND METHODS
Materials and animals
IPG gel strips (pH 4-7, 18 cm), ampholyte, SDS, acryla-
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Proteomic Analysis of Rat Brains Following Exposure to
Electroconvulsive Therapy
Electroconvulsive therapy (ECT) is one of the most effective treatments used in
psychiatry to date. The mechanisms of ECT action, however, are the least under-
stood and still unclear. As a tool to elucidate the mechanisms of action of ECT, we
employed proteomic analysis based on the identification of differentially expressed
proteins after exposure to repeated ECT in rat brains. The expression of proteins
was visualized by silver stain after two-dimensional gel electrophoresis. Of 24 dif-
ferentially expressed protein spots (p<0.05 by Student t-test), six different proteins
from 7 spots were identified by matrix-assisted laser desorption/ionization time-of
flight (MALDI-TOF)/mass spectrometry. Among the identified proteins, there were
five dominantly expressed proteins in the ECT-treated rat brain tissues (p<0.05);
S100 protein beta chain, 14-3-3 protein zeta/delta, similar to ubiquitin-like 1 (sentrin)
activating enzyme subunit 1, suppressor of G2 allele of SKP1 homolog, and phos-
phatidylinositol transfer protein alpha. The expression of only one protein, ACY1
protein, was repressed (p<0.05). These findings likely serve for a better understand-
ing of mechanisms involved in the therapeutic effects of ECT.
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mide, N,N′ -methylene-bis-acrylamide, TEMED, ammoni-
um persulfate, dithiothreitol (DTT), urea, Tris, glycine, glyc-
erol, and CHAPS were purchased from Bio-Rad (Hercules,
CA, U.S.A.). Silver nitrate, Coomassie Brilliant Blue G-250,
TCA, iodoacetamide, and CHCA (α -cyano-4-hydroxycinnam-
ic acid) were from Sigma-Aldrich (St. Louis, MO, U.S.A.).
Methyl alcohol, ethyl alcohol, phosphoric acid, acetic acid, and
formaldehyde were purchased from Merck (Darmstadt, Ger-
many). Sequencing grade modified trypsin was obtained from
Promega (Madison, WI, U.S.A.). Other reagents were obtained
from Sigma-Aldrich or Merck.
Four to six months male rats (Sprague Dawley, 200-350 g;
ACE Animals, Boyertown, PA, U.S.A.) were used in this study.
Rats were housed in groups of five with free access to food and
water, and the animal room was maintained at approximate-
ly 23℃with a 12 hr light/dark cycle. The ECT (or electrocon-
vulsive shock) was applied via bilateral ear clip electrodes. The
shock, a square wave pulse (pulse width, 0.7 msec; 50 Hz) of
50 mA, was administered for 1 sec to provide a tonic seizure
phase. ECT-treated animals (N=8) were given one ECT per
day for 14 consecutive days. The control rats (N=8) were han-
dled in the same condition with no current. All animal exper-
iments were approved by the Institutional Review Board and
carried out in accordance with the principles of laboratory ani-
mal care. The rat brains were weighed, frozen on dry ice and
stored at -70℃.
Sample preparation for two-dimensional gel
electrophoresis (2-DE)
The frozen rat brain tissues (-2.5 g) were washed three times
with phosphate-buffered saline (pH 7.2), and homogenized
in 5 mL homogenization buffer (50 mM Tris-HCl [pH 7.2]
and 150 mM NaCl) containing 1× protease inhibitor cock-
tail (Promega) using an Ultra-Turrax T8 Homogenizer (IKA,
Staufen, Germany).
TCA-precipitated proteins were washed once in diethyl
ether and dried under air stream. The dried pellets were dis-
solved with sonication in the lysis buffer (40 mM Tris, 8 M
urea, 4% CHAPS, 100 mM DTT, and 2% ampholyte), and
were centrifuged at 15,000 rpm (100,000×g) for 15 min
at 4℃. The resulting supernatant was kept at -70℃ until
use. Protein concentration was determined by the Bradford
method using bovine serum albumin as a standard (5).
2-DE
The IPG gel strips were rehydrated in a swelling solution
(8 M urea, 2% CHAPS, 100 mM DTT, 0.5% pH 4-7 IPG
buffer, and bromophenol blue) containing 50 μ g (for silver
staining) or 500 μ g (for Coomassie blue staining) proteins for
12 hr at 20℃, and applied to strips by overnight rehydration
at 50 V (6). Proteins were focused for 10,000 V within 3 hr,
and maintained at 10,000 V for 7 hr at 20℃ using Protean
IEF Cell (Bio-Rad, Hercules, CA, U.S.A.). After the IEF pro-
cedure, the strips were equilibrated as described (7). Separa-
tion in the second dimension by SDS-PAGE at 16℃ at 5
mA/cm (constant current) for the initial 1 hr and 10 mA/cm
thereafter. Protein visualization by silver or Coomassie blue
staining was performed as described (7).
Image analysis and protein identification
Protein patterns in the gel were recorded as digitalized im-
ages using a high-resolution scanner (GS-710 Calibrated Imag-
ing Densitometer, Bio-Rad). The scanned gel image was ana-
lyzed using a standard protocol for PDQuest software (Bio-
Rad). For all spot intensity calculations, normalized values
were used and expressed in ppm. In-gel digestion of protein
spots with trypsin was performed as described (7). The tryp-
tic peptides were redissolved in a solution containing water,
acetonitrile, and trifluoroacetic acid (93:5:2), and the solution
was treated for 5 min in a bath sonicator. Target preparation
was carried out by solution phase nitrocellulose method. Sat-
urated solution of CHCA (40 mg/mL) and nitrocellulose (NC)
solution (20 mg/mL) was prepared separately in acetone. A
mixture of CHCA- and NC solution, and 2-propanol was pre-
pared at a ratio of 2:1:1. Peptide calibrants (50-200 fM of
each), des-Arg-bradykinin (monoisotopic mass, 904.4681),
and neurotensin (1672.9715), were added and the mixture
solution was then spotted on the target and dried. The dried
samples were washed with 5 μ L of 5% formic acid for 10 sec,
followed by 5 μ L of Milli-Q water for 10 sec, and then the
dried spots were analyzed in a Voyager-DETM STR MALDI-
TOF mass spectrometer (PerSeptive Biosystems, Framing-
ham, MA, U.S.A.). The spectrometer was run in positive
ion mode and in reflector mode with the following settings:
accelerating voltage, 20 kV; grid voltage, 76%; guide wire
voltage, 0.01%; and a delay of 150 ns. The low mass gate
was set at 500 m/z. Proteins were identified by peptide mass
fingerprinting with the search programs MS-FIT (http://pro-
spector.ucsf.edu/ucsfhtml3.4/msfit.htm).
RESULTS
We analyzed the proteomic profiles of the ECT-treated rat
brain tissues and the normal control brain tissues with each
8 pairs. Spots representing proteins that were differentially
expressed in the ECT-treated rat brains were selected (p<0.05
by Student’s t-test). A total of 918 spots from the control group
and 962 spots from the ECT-treated group were visualized
in a gel (pH range from 4-7 and molecular mass range from
10-100 kDa) (Fig. 1). The overall protein expression patterns
in the ECT-treated and the normal brain tissues were quite
similar except for some areas. The protein identities from all
the spots were entered in the composite gel database so that
any changes in the protein expression could be determined for134 C.S. Lee, K.R. Kang, J.-Y. Lee, et al.
each protein spot. The integrated protein intensity was deter-
mined for each identified spot in eight gels each from the
ECT-treated and normal brains. The mean intensity of each
spot was calculated by its silver stain intensity and the rela-
tive intensities between the ECT-treated and normal brains.
Five proteins were dominantly expressed in the ECT-treated
rat brain tissues and one protein was revealed largely repressed,
and these proteins were found with a statistical significance.
Some of these proteins have been identified by mass spectrom-
etry. A typical mass spectrum of a protein, 14-3-3 protein zeta/
delta, was shown in Fig. 2. Total 6 proteins from 7 spots were
identified. The expression level of each protein in both ECT-
treated and normal tissue was indicated by the density val-
ues (Fig. 3). Their predicted values of isoelectrical point (pI)
and molecular weight (M.W.) were summarized in Table 1,
and the values were compatible to those of acquired from the
gels. The sequence coverage of proteins isolated from the pep-
tide mass matching in a program was acceptable (20-40%
ranges). Five proteins were dominantly expressed in the ECT-
treated rat brain tissues with a statistical significance; S100
protein beta chain (S100B), 14-3-3 protein zeta/delta, simi-
lar to ubiquitin-like 1 (sentrin) activating enzyme subunit 1,
suppressor of G2 allele of SKP1 homolog and phosphatidyli-
nositol transfer protein alpha (PI-TPα ) (Fig. 1, 3A). One
protein, ACY1 protein, was revealed largely repressed (Fig.
1, 3B).
DISCUSSION
Proteomics provides a powerful tool for the identification
of proteins differentially expressed after exposure to ECT. In
this study, 24 protein spots whose expression was changed
after ECT were shown to have either increased or decreased
expression in the ECT-treated rat brain tissues. Three ranges
of IPG gel strips (pI 3-10, 4-7, and 6-9) were used for IEF
with similar results in the slightly different resolution, but
pI4-7 strip was selected for the optimum condition (data not
shown). Among them, six proteins were identified as S100B,
14-3-3 protein zeta/delta, PI-TPα , similar to ubiquitin-like
1 (sentrin) activating enzyme subunit 1, suppressor of G2 allele
of SKP1 homolog and ACY1 protein by MALDI-TOF/mass
spectrometry.
Expression of S100B was increased after ECT-treated brain
Fig. 1. Two-dimensional gel electrophoresis patterns of proteins from the ECT-treated rat brain tissue (A) and normal control brain tissue (B).




















Fig. 2. Peptide mass fingerprinting of 14-3-3 protein zeta/delta. The
spot P35213 was in-gel digested with trypsin. After desalting, the
peptide mixture was analyzed by MALDI-TOF/mass spectrometry.
The abscissa represents the mass/charge ratio of ions detected
in the MALDI-TOF experiments. The ordinate denotes the relative
intensity of the averaged ion current in arbitrary units. The peaks
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Fig. 3. 2-DE patterns showing up-regulated protein spots (A, indicated by arrowheads) and down-regulated spot (B, indicated by circle)
in ECT-treated rat brain tissues (left panel) compared with control brain tissues (middle panel). The histogram in the right panel shows the





























Similar to ubiquitin-like 1







































*The ratio of normalized spot intensities of control and ECT-treated rat brain tissues. The ratio was calculated for each paired samples in rat brains. The arrows
indicate the intensities of up-regulated protein spots in ECT-treated brains (↑) and that of down-regulated spot in ECT-treated brains (↓).
ECT, electroconvulsive therapy.
Accession number Protein identified  pI/MW (kDa)
Abundance level* Sequence
(mean±SD) coverage
P04631 S100 protein beta chain  4.5/10.7 ↑2.8±2.1 40%
P35213 14-3-3 protein zeta/delta  4.7/27.7 ↑2.6±1.9 20%
34855215 Similar to ubiquitin-like 1 (sentrin) activating enzyme subunit 1 5.0/39.5 ↑4.7±3.9 37%
Q9CX34 Suppressor of G2 allele of SKP1 homolog 5.3/38.1 ↑3.0±2.6 37%
P16446 Phosphatidylinositol transfer protein alpha isoform  6.0/31.7 ↑2.2±0.7 35%
P00787 ACY1 protein  6.0/45.8 ↓1.8±2.3 40%
Table 1. Differentially expressed proteins in normal and ECT-treated rat brains
A
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compared with control rat brain. S100B is a calcium-binding
protein, produced and secreted by astrocytes and it modulated
the proliferation and differentiation of neurons and glia (8).
Increased levels of this protein are associated with brain dam-
age and its persistent elevation appears to be involved in neu-
rodegenerative disorders including schizophrenia (9). Cere-
brospinal fluid levels of S100B of rats submitted to repeat-
ed-ECT were significantly increased (10). Whether S100B
levels are elevated due to injured astrocytes and a disrupted
blood brain barrier or by active secretion of S100B by astro-
cytes, it is remained to be clarified by further studies.
The 14-3-3 proteins belong to a family consisting of high-
ly conserved acidic proteins with molecular weights of 25-30
kDa. The 14-3-3 proteins participate in phosphorylation-de-
pendent protein-protein interactions that control progression
through the cell cycle, initiation and maintenance of DNA
damage checkpoints, activation of MAP kinases, prevention
of apoptosis and coordination of integrin signaling and cyto-
skeletal dynamics (11, 12). Alterations of the expression of
14-3-3 proteins have been associated with several human dis-
eases such as cancer, heart disease and a variety of neurodegen-
erative disorders including Cruezfeldt-Jacob disease and Al-
zheimer’s disease. The 14-3-3 proteins have been implicated
by several recent studies in the potential genetic bases of sc-
hizophrenia (13, 14). In schizophrenia, mRNA levels of one
of the 14-3-3 membrane (eta) proteins have been reported to
be significantly decreased in post-mortem cerebellum sam-
ples obtained form medicated subjects with schizophrenia (15).
Recently, Middleton et al. reported that the 14-3-3 beta tran-
script may be unique among the 14-3-3 genes due to its asso-
ciated increase in response to haloperidol and decrease in the
disease state (16). Expression of the 14-3-3 protein zeta/delta
in the ECT-treated rat brain was increased in this study. This
finding might be associated with the therapeutic mechanism
of ECT on psychotic symptoms.
Expression of phosphatidylinositol transfer proteins was
increased after ECT. PI-TPs are responsible for the transport
of phosphatidylinositol (PI) and other phospholipids between
membranes. PI-TPs play a role in the delivery of PI to PI-4-
kinase, which synthesizes PI-4,5-biphosphate (PIP2). Because
of the high affinity of PI-TPs for PIP and PIP2, these lipids
remain bound to PI-TPs that may also deliver these substances
for PLC (17). Kauffmann et al. (18) have identified PI-TPα
as an essential component for ensuring substrate supply to
PLC. This enzyme hydrolyzes PIP2 to generate the second
messengers: diacylglycerol (DAG) and inositol trisphosphate
(IP3). In the next step, DAG activates PKC via phosphory-
lation which initiates the mitogen activated protein kinase
(MAPK) cascade. A second messenger generating system that
may be involved in mood regulation involves phosphoinosi-
tide metabolism (19, 20). In this system, the plasma mem-
brane located lipid PIP2 is hydrolyzed to a postsynaptic sec-
ond messenger that contributes to chronic cell stimulation by
altering the electrical activity in the neuron. Inositol formed
during this process is recycled by the enzyme inositol mono-
phosphatase. Cells in the central nervous system have limit-
ed access to plasma sources of inositol and depend on its syn-
thesis for the transduction of neuronal signals. Lithium in ther-
apeutic concentrations blocks the activity of inositol monop-
hosphatase, inhibiting the hydrolysis of intermediate inosi-
tol phosphates into inositol, which is necessary for the resyn-
thesis of PIP2 (21). As a result, PIP2 levels are depleted, and
the lipid is no longer able to stimulate the formation of ade-
quate quantities of the second messenger or alter electrical
activity. Therefore, increased expression of PI-TPαin ECT-
treated rat brain may be associated with a mood stabilizing
effect of ECT.
The ACY1 protein is a homodimeric zinc-binding metal-
loenzyme located in the cytosol (22). The ACY1 protein is
usually involved in detoxification processes. It hydrolyzes a
variety of N-acylated amino acids generating free amino acids
and may be involved in the synthesis of hippurate that is formed
during detoxification of aromatic compounds (23). A dimin-
ished expression of this enzyme has also been found in lung
cancer cell lines of small cell type and pulmonary tumors (24).
However, its physiological role remains unclear. The physi-
ological role of the other identified proteins such as similar
to ubiquitin-like 1 (sentrin) activating enzyme subunit 1 and
suppressor of G2 allele of SKP1 homolog is still unknown.
Further studies are required to determine whether these pro-
teins are associated with the mechanisms of ECT in regard to
its therapeutic and/or adverse effects.
In conclusion, the current study was designed to identify
differentially expressed proteins in rat brains following expo-
sure to repeated ECT using proteomic analysis. Twenty four
protein spots whose expression was increased or decreased after
exposure to ECT were isolated. Six different proteins from 7
spots, whose levels were altered by more than 3.0-fold in more
than four of the eight pairs analyzed, were identified by MA-
LDI-TOF/mass spectrometry. These proteins were ACY1 pro-
tein, S100B, 14-3-3 protein zeta/delta, similar to ubiquitin-
like 1 (sentrin) activating enzyme subunit 1, PI-TPαand sup-
pressor of G2 allele of SKP1 homolog. Taken together, the
results obtained might help us to find a valuable resource for
the investigation of mechanisms involved in the therapeutic
and adverse effects of ECT.
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